Antibiotic-associated diarrhoea Digestive System
Conditions
Interventions
Patients were randomized (2:2:1) to receive 200 ml of:
1. placebo yoghourt (S. thermophilus 10^9 ufc/ml, L bulgaricus 10^7 ufc/ml), (placebo group)
2. probiotic yoghourt (previous plus L. acidophilus
Sponsors
University Hospital Foundation Alcorcón (Hospital Universitario Fundación Alcorcón) (Spain)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adults patients, both male and non-pregnant female, older than 18 years who are prescribed amoxycilline-clavulanate or levofloxacin (oral or intravenous) in their treatments and are able to eat and drink 2. Patients or relatives must be able to give written informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnancy 2. Allergy to penicillins or levofloxacin 3. Known lactose intolerance or intolerance to dairy products 4. Diarrhoea on admission or within the preceding week 5. Reported recurrent diarrhoea or bowel disease that could result in diarrhoea 6. Severe immunosuppression 7. Active neoplasia 8. HIV infection 9. Regular probiotic treatment before admission, or laxative use or enema in the 48 hours before admission
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of diarrhoea up to one month after the end of antibiotic therapy. WHO definition of diarrhoea was used: 3 or more loose or watery stools per day for two or more days. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Severity of diarrhoea defined as the maximum number of stools per day; length of diarrhoea (days with more than two loose stools) 2. Necessity to stop antibiotic treatment to treat AAD 3. Necessity to use endovenous fluid to treat AAD 4. Prolonged hospital admission or readmission because of AAD 5. Mortality 6. Tolerance to yoghourt and compliance All outcomes were evaluated, followed-up for one month. | — |
Countries
Spain
Outcome results
None listed